Eli Lilly on Tuesday sued 10 medical spas, wellness clinics and compounding pharmacies across the U.S. for allegedly selling cheaper, unauthorized versions of the company's diabetes drug Mounjaro. Eli Lilly specifically accuses the spas, clinics and compounding pharmacies of marketing and selling "compounded" drug products that claim to contain tirzepatide, the active ingredient in Mounjaro. Compounded drugs are custom-made versions of a treatment that are not approved by the U.S. Food and Drug Administration. The FDA has not issued a warning about compounded versions of tirzepatide. However, Mounjaro, Ozempic and Wegovy have all been in short supply in the U.S. since last year, according to the FDA's database.

---

Persons: Eli Lilly, Eli Lilly grapples, Ozempic Organizations: Novo Nordisk, Pharmacy, U.S . Food, Drug Administration, FDA Locations: Provo , Utah, U.S, Florida , Texas , Arizona, Georgia, Minnesota, South Carolina, Utah, Florida